The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program recently announced $8 million in new contract funding opportunities to assist innovative small businesses with cancer research and technology development. This year, NCI SBIR has announced 12 new contract funding opportunities in a range of novel technology areas that you may want to share with your constituents.
The current NCI SBIR FY2012 solicitation provides funding opportunities to small businesses and continues to support the research and development of many areas of interest to the NCI including, but not limited to: Anti-Cancer Agents, In Vitro and Companion Diagnostics, Radiotherapy, Device Development, Nanotechnology-based Sensors and Therapeutics, Imaging Technology and Agents.
In addition, the NCI SBIR Program has also announced three NIH Technology Transfer (TT) Inventions released as contract topics. The goal of each SBIR-TT topic is to identify a small business which can obtain both SBIR funding and licenses to the technology to perform the necessary R&D to advance the technology towards commercialization.
The FY2012 technology transfer contract topics are:
- 310 Simplified Tumor Microarray Instrument for Clinical and Research Settings
- 311 High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
- 075 A Low Molecular Weight Thyroid-Stimulating Hormone Receptor Agonist for Thyroid Cancer – Funding will be provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), while the receipt, review, and contracting will be handled by NCI.
For a full list of contract funding opportunities currently available, please click here.
Please let me know if you have any questions or would like me to connect you with someone from SBIR to learn more. Thank you in advance for your consideration.
Assistant Account Executive
Feinstein Kean Healthcare | An Ogilvy Company
245 First Street, 14th Floor, Cambridge, MA 02142
d: 617.761.6788 | m: 917.435.0506 | o: 617.577.8110